BioNexus Gene Lab Corp
BGLC Nasdaq
SEC CIK 1737523
Follow BioNexus Gene Lab
Weekly email: filings, results, news
Revenue, last quarter
$76.2K
−96.6% vs same quarter last year
Net income
−$286.5K
+53.5% vs same quarter last year
EPS, diluted
−$0.12
+65.6% vs same quarter last year
Operating cash flow
−$422.5K
+42.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $7.4M | −$3M |
| FY24 | $9.5M | −$1.6M |
| FY23 | $9.8M | −$2.6M |
| FY22 | $10.9M | −$356K |
| FY21 | $13.4M | $751.6K |
| FY20 | $11.4M | $1.1M |
| FY19 | $127K | −$246.5K |
| FY18 | $212.3K | $26.5K |
| FY17 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 14.6% | −39.9% | −40.2% |
| FY24 | 13.6% | −16.5% | −16.8% |
| FY23 | 13.6% | −26.5% | −26.9% |
| FY22 | 11.5% | −2.7% | −3.3% |
| FY21 | 17% | 7.9% | 5.6% |
| FY20 | 15.1% | 11.2% | 9.6% |
| FY19 | 44% | −217.2% | −194.1% |
| FY18 | 13.5% | 28.2% | 12.5% |
| FY17 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$1.9M |
| FY24 | −$2.3M |
| FY23 | −$2M |
| FY22 | $551.8K |
| FY21 | $6K |
| FY20 | $131.1K |
| FY19 | −$230.1K |
| FY18 | −$313.7K |
| FY17 | - |
- BioNexus Gene Lab
- Healthcare median
Show the numbers
| Year | BioNexus Gene Lab | Healthcare median |
|---|---|---|
| FY25 | −40.2% | −63.2% |
| FY24 | −16.8% | −86.4% |
| FY23 | −26.9% | −123.6% |
| FY22 | −3.3% | −138.2% |
| FY21 | 5.6% | −139.8% |
| FY20 | 9.6% | −143.7% |
| FY19 | −194.1% | −143.3% |
| FY18 | 12.5% | −173.4% |
| FY17 | - | −166.7% |
News
No stories filed under BioNexus Gene Lab yet - coverage appears here as the news feed clusters it.